title: Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis.
abstract: In a randomized, open-label, controlled, multicentre study, the clinical and bacteriological efficacy, safety and tolerability of oral gemifloxacin (320 mg once daily, 5 days) was compared with sequential intravenous (i.v.) ceftriaxone (1 g once daily, maximum 3 days) followed by oral cefuroxime axetil (500 mg twice daily, maximum 7 days) in adult hospitalized patients with acute exacerbations of chronic bronchitis (AECB) (n = 274). The clinical success rates at follow-up (21-28 days post-therapy) in the clinical per-protocol population (the primary endpoint) were 86.8% (105/121) for gemifloxacin vs. 81.3% (91/112) for ceftriaxone/cefuroxime (treatment difference = 5.5,95% CI -3.9,14.9). The corresponding clinical results in the clinical intention-to-treat (ITT) population were 82.6% (114/138) vs. 72.1% (98/136), respectively (treatment difference = 10.5,95% CI 0.7, 20.4).Thus, gemifloxacin had significantly higher clinical success rates than ceftriaxone/cefuroxime. The median time to discharge was 9 days in the gemifloxacin group vs. 11 days in the ceftriaxone/cefuroxime group (P = 0.04, Wilcoxon test). At follow-up, 120/138 (87.0%) gemifloxacin-treated patients had been discharged from hospital, compared with 111/136 (81.6%) ceftriaxone/cefuroxime-treated patients in the clinical ITT population. Both treatments were generally well tolerated and there was no significant difference between the treatment groups in the incidence or type of adverse events reported. A 5-day course of oral gemifloxacin was shown by this study to be at least equivalent to sequential i.v. ceftriaxone/cefuroxime axetil (for up to 10 days) in patients with AECB who require hospital treatment.
authors.affiliation: Royal Brompton Hospital, London, U.K. r.wilson@rbh.nthames.nhs.uk
authors.forename: R
authors.initials: R
authors.lastname: Wilson
authors.forename: C
authors.initials: C
authors.lastname: Langan
authors.forename: P
authors.initials: P
authors.lastname: Ball
authors.forename: K
authors.initials: K
authors.lastname: Bateman
authors.forename: R
authors.initials: R
authors.lastname: Pypstra
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000503:physiopathology; D029481:Bronchitis, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D002443:Ceftriaxone / Q000008:administration & dosage*; D002444:Cefuroxime / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D005541:Forced Expiratory Volume / Q000187:drug effects; D000077735:Gemifloxacin; D006760:Hospitalization; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009287:Naphthyridines / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D002443:Ceftriaxone; D002444:Cefuroxime; D000077735:Gemifloxacin; C040738:cefuroxime axetil